HRP20250727T1 - Inhibitori metalotioneina za liječenje dijabetesa, hepatitisa, i/ili upalne bolesti jetre - Google Patents

Inhibitori metalotioneina za liječenje dijabetesa, hepatitisa, i/ili upalne bolesti jetre

Info

Publication number
HRP20250727T1
HRP20250727T1 HRP20250727TT HRP20250727T HRP20250727T1 HR P20250727 T1 HRP20250727 T1 HR P20250727T1 HR P20250727T T HRP20250727T T HR P20250727TT HR P20250727 T HRP20250727 T HR P20250727T HR P20250727 T1 HRP20250727 T1 HR P20250727T1
Authority
HR
Croatia
Prior art keywords
composition
use according
subject
diabetes
liver disease
Prior art date
Application number
HRP20250727TT
Other languages
English (en)
Croatian (hr)
Inventor
Michael A. Lynes
Yu-Hua Tseng
Matthew D. LYNES
Original Assignee
University Of Connecticut
Joslin Diabetes Center, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Connecticut, Joslin Diabetes Center, Inc. filed Critical University Of Connecticut
Publication of HRP20250727T1 publication Critical patent/HRP20250727T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HRP20250727TT 2018-01-17 2019-01-17 Inhibitori metalotioneina za liječenje dijabetesa, hepatitisa, i/ili upalne bolesti jetre HRP20250727T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862618332P 2018-01-17 2018-01-17
PCT/US2019/013934 WO2019143767A1 (en) 2018-01-17 2019-01-17 Methods for treating diabetes, hepatitis, and/or inflammatory liver disease
EP19703874.8A EP3740282B1 (en) 2018-01-17 2019-01-17 Metallothionein inhibitors for treating diabetes, hepatitis, and/or inflammatory liver disease

Publications (1)

Publication Number Publication Date
HRP20250727T1 true HRP20250727T1 (hr) 2025-10-24

Family

ID=65324621

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20250727TT HRP20250727T1 (hr) 2018-01-17 2019-01-17 Inhibitori metalotioneina za liječenje dijabetesa, hepatitisa, i/ili upalne bolesti jetre

Country Status (20)

Country Link
US (3) US11866488B2 (enExample)
EP (2) EP3740282B1 (enExample)
JP (2) JP7486423B2 (enExample)
KR (1) KR20200110659A (enExample)
CN (2) CN120267797A (enExample)
AU (2) AU2019209491B2 (enExample)
BR (1) BR112020014346A2 (enExample)
CA (1) CA3088661A1 (enExample)
EA (1) EA202091533A1 (enExample)
ES (1) ES3033317T3 (enExample)
HR (1) HRP20250727T1 (enExample)
HU (1) HUE072418T2 (enExample)
IL (2) IL276097B2 (enExample)
MX (1) MX2020007384A (enExample)
PH (1) PH12020551076A1 (enExample)
PL (1) PL3740282T3 (enExample)
RS (1) RS66918B1 (enExample)
SG (1) SG11202006421RA (enExample)
SM (1) SMT202500233T1 (enExample)
WO (1) WO2019143767A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020234718A1 (en) 2019-03-13 2023-05-18 Tearsolutions, Inc. Compositions and methods for promoting islet viability and enhancing insulin secretion
AU2020315367A1 (en) 2019-07-15 2022-02-03 University Of Connecticut Metallothionein antibodies and their use
CN110551726B (zh) * 2019-09-06 2021-04-09 上海市肺科医院 一种结核杆菌阿拉伯半乳聚糖适配子及其应用
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
KR102191405B1 (ko) * 2020-09-15 2020-12-16 주식회사 에이스바이오메드 간 질환 예방 또는 치료용 조성물
CN115317502B (zh) * 2021-12-21 2023-07-07 青岛市市立医院 一种线性硬毛藻提取的粗多糖在制备非酒精性脂肪性肝药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20030007973A1 (en) 2001-06-22 2003-01-09 Lynes Michael A. Methods and compositions for manipulation of the immune response using anti-metallothionein antibody
WO2007012188A1 (en) 2005-07-27 2007-02-01 Qinghua Wang GLP/1/EXENDM 4 IgG Fc FUSION CONSTRUCTS FOR TREATMENT OF DIABETES
CN102725312B (zh) * 2009-10-20 2014-10-01 佐治亚州立大学研究基金会公司 用于糖尿病治疗和β细胞成像的蛋白药物
EP2627638B1 (en) 2010-10-14 2017-07-12 Immunahr AB 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators.
CA2840282C (en) * 2011-07-08 2018-11-13 Universiteit Gent Use of antagonists targeting metallothionein to treat intestinal inflammation
US20160215042A1 (en) * 2013-04-19 2016-07-28 The Brigham And Women's Hospital, Inc. Methods for modulating immune responses during chronic immune conditions by targeting metallothioneins
TR201402685A1 (tr) 2014-03-06 2015-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vildagliptinin farmasotik formulasyonları.
US10695406B2 (en) * 2014-05-27 2020-06-30 The University Of Queensland Modulation of cellular stress using a B-cell oxidative and/or endoplasmic reticulum stress inhibitor and a targeting agent
BR112017001931A2 (pt) 2014-08-07 2017-11-28 Regulus Therapeutics Inc direcionamento de micrornas para distúrbios metabólicos

Also Published As

Publication number Publication date
EP3740282C0 (en) 2025-03-26
CN111801140B (zh) 2025-05-16
WO2019143767A1 (en) 2019-07-25
IL316486A (en) 2024-12-01
EP3740282B1 (en) 2025-03-26
US20240025981A1 (en) 2024-01-25
EP4596042A3 (en) 2025-11-05
KR20200110659A (ko) 2020-09-24
AU2022215285A1 (en) 2022-09-29
JP2021511296A (ja) 2021-05-06
AU2019209491A1 (en) 2020-07-23
JP2024028454A (ja) 2024-03-04
IL276097A (en) 2020-08-31
EP4596042A2 (en) 2025-08-06
JP7486423B2 (ja) 2024-05-17
EP3740282A1 (en) 2020-11-25
IL276097B2 (en) 2025-04-01
CN111801140A (zh) 2020-10-20
AU2022215285B2 (en) 2024-08-29
PH12020551076A1 (en) 2021-08-16
AU2019209491B2 (en) 2022-05-19
PL3740282T3 (pl) 2025-07-21
IL276097B1 (en) 2024-12-01
US20200369757A1 (en) 2020-11-26
EA202091533A1 (ru) 2020-11-16
ES3033317T3 (en) 2025-08-01
HUE072418T2 (hu) 2025-11-28
US20240067710A1 (en) 2024-02-29
CN120267797A (zh) 2025-07-08
RS66918B1 (sr) 2025-07-31
SMT202500233T1 (it) 2025-07-22
US11866488B2 (en) 2024-01-09
BR112020014346A2 (pt) 2020-12-08
CA3088661A1 (en) 2019-07-25
SG11202006421RA (en) 2020-08-28
MX2020007384A (es) 2020-10-19

Similar Documents

Publication Publication Date Title
HRP20250727T1 (hr) Inhibitori metalotioneina za liječenje dijabetesa, hepatitisa, i/ili upalne bolesti jetre
Nishizawa et al. IGF-I induces senescence of hepatic stellate cells and limits fibrosis in a p53-dependent manner
Chen et al. Induction of leptin resistance through direct interaction of C-reactive protein with leptin
Neuschwander-Tetri et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Giannone et al. Reversal of liver fibrosis by the antagonism of endocannabinoid CB1 receptor in a rat model of CCl4-induced advanced cirrhosis
Kouno et al. Selective PPARδ agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway
Cai et al. Yinchenhao decoction alleviates liver fibrosis by regulating bile acid metabolism and TGF-β/Smad/ERK signalling pathway
Sumida et al. Current and new pharmacotherapy options for non-alcoholic steatohepatitis
HRP20180445T1 (hr) Il-22 za uporabu u liječenju mikrobnih poremećaja
Sans et al. The differential expression of cide family members is associated with nafld progression from steatosis to steatohepatitis
Guo et al. WNT/β-catenin signaling regulates cigarette smoke-induced airway inflammation via the PPARδ/p38 pathway
Zhang et al. Circulating asprosin levels are increased in patients with type 2 diabetes and associated with early-stage diabetic kidney disease
Tiessen et al. Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial
Zhang et al. Recombinant adiponectin ameliorates liver ischemia reperfusion injury via activating the AMPK/eNOS pathway
Jiao et al. Distinct downstream signaling and the roles of VEGF and PlGF in high glucose-mediated injuries of human retinal endothelial cells in culture
Peng et al. Nobiletin alleviates palmitic acid‑induced NLRP3 inflammasome activation in a sirtuin 1‑dependent manner in AML‑12 cells
Zhang et al. The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor
Chen et al. Targeting SYK of monocyte-derived macrophages regulates liver fibrosis via crosstalking with Erk/Hif1α and remodeling liver inflammatory environment
Wagner et al. Nuclear bile acid receptor farnesoid X receptor meets nuclear factor‐κB: New insights into hepatic inflammation
Cui et al. Allium victorialis L. extracts promote activity of FXR to ameliorate alcoholic liver disease: Targeting liver lipid deposition and inflammation
FI3565592T3 (fi) Metabolisten tautien hoitaminen estämällä myostatiinin aktivaatio
Wepler et al. Effects of the PPAR-β/δ agonist GW0742 during resuscitated porcine septic shock
Mor et al. Targeting CCL24 in inflammatory and fibrotic diseases: rationale and results from three CM-101 phase 1 studies
Francque et al. Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction–associated steatohepatitis
Vallon et al. Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS